| Asthma |
NCT04987944: Safety and Efficacy Active Drug vs. Placebo in Subjects With Asthma |
|
|
| Terminated | 1b | 15 | Canada | Zavegepant, BHV3500, Placebo | Pfizer | Asthma | 03/23 | 04/23 | | |
ACTRN12607000466448: An intervention to reduce the prevalence and impact of asthma and food allergies occurring in association with atopic dermatitis through improved skin care in infants and young children. |
|
|
| Not yet recruiting | 1 | 700 | | | Fred Bauer Research Fund, National Health and Medical Rsearch Council | Asthma, Atopic Dermatitis | | | | |
| Completed | 1 | 0 | RestOfWorld | RPC4046 | Receptos | Other Inflammatory Diseases / Healthy Sub.; Asthma | | | | |
| Recruiting | 1 | 100 | | | Hunter Medical Research Institute, Asthma Australia | Asthma | | | | |
ChiCTR-TRC-13003324: The efficacy and safety evaluation of Tongchuanqing Granule in children's chronic persistent period of Bronchial Asthma with dyspnea due to deficiency syndrome: a multi-center,Randomized,doubled-blind, placebo-controlled trial |
|
|
| Completed | 1 | 480 | | Tongchuanqing Granules(5 to 7 years: Take 1 bag (3G), 2 times a day. 8 to 10 years: take 1.5 bag (4.5g), 2 times a day. 11 to 14 years: take 2 bag (6g), 2 times a day) ;placebo (5 to 7 years: Take 1 bag (3G), 2 times a day. 8 to 10 years: take 1.5 bag (4.5g), 2 times a day. 11 to 14 years: take 2 bag (6g), 2 times a day) | First Teaching Hospital of Tianjin University of Traditional Chinese Medicine; Yangtze River Pharmceutical Group Nanjin Hailin Co., Ltd, Yangtze River Pharmceutical Group Nanjin Hailin Co.,Ltd | Asthma | | | | |
NCT00753701: A Study of Repeat Inhaled Doses of GW642444M in Healthy Japanese Male Subjects |
|
|
| Not yet recruiting | 1 | 32 | Japan | GW642444 | GlaxoSmithKline | Asthma, COPD | | | | |
ChiCTR-ENRC-10000864: The Association between ADAM33 Gene Polymorphisms and asthma in East Chinese Han Population |
|
|
| Completed | 1 | 230 | | NA ;NA | Department of Respiratory Medicine, Zhongshan Hospital, Fudan University, Shanghai, China; Board of Health in Shanghai, Scientific Development Foundation of Board of Health in Shanghai | asthma | | | | |
ChiCTR-OCH-11001292: Effect of summer-acupoint-application-therapy (SAAT) on reducing exacerbation frequency of Chronic Lung Diseases in winter |
|
|
| Completed | 1 | 14704 | | SAAT I ;SAAT II ;SAAT III ;SAAT IV ;SAAT IV | Institute of Basic Research In Clinical Medicine, China Academy of Chinese Medical Sciences; China Academy of Chinese Medical Sciences, National Key Technology R&D Program in the 11th Five year Plan of China | Chronic Lung Diseases, including bronchial asthma, COPD, chronic bronchitis, allergic rhinitis and RRTL | | | | |
ChiCTR-TRC-10000831: The relationship of airway hyperresponsiveness changes and gamma delta T cells with aerosol inhalation of Mycobacterium Phlei in light moderate asthma patients |
|
|
| Completed | 1 | 36 | | Utilin 1.72 ug*2+Saline 3ml, inhalation, once a day, 5 days/a course of treament.6days, one month, 3 months, 6 months, 1 year after treament review the indicator respectively, and carry one intensive therapy, 3 days/one course of treatment. Use Ventolin if they need, inform the patients inhaled Ventolin twice per day with 2 spray while use Utilin at the beginning of 1-3 days. ;Seretide 50/100ug, do falling-rising ladder adjustment according GINA standard during the observation period. 6 days, one month, 3 months, 6 months, 1 year after treament review the indicator respectively, can use Ventolin if they need during the period ;As a negative control of group A apply saline 5ml,inhalation, once perday, 5 days/a course of treatment. At the beginning of 1-3days inform the patients inhaled Ventolin twice per day with 2 spray. Based on ethical objections, do 5days observation, If overcome non-effective results (mainly refer to no improvement in symptoms. review no reduces airway responsiveness) should combined the patients to group A or B;if overcome effective resullts, do the same way of group A, program the intensive ther | Department of Public Health of Guangxi Zhuang Autonomous Region; 1st Affiliate Hospital of Guangxi Medical University, Department of Public Health of Guangxi Zhuang Autonomous Region | asthma | | | | |
2012-003241-15: A study to develop a non-invasive version of the diagnostic test of the body's ability to produce enough stress hormone. |
|
|
| Not yet recruiting | 1 | 258 | Europe | 100mcg tetracosactide (in a 1:1 mix with chitosan), 500 mcg tetracosactide, 500 mcg tetracosactide (in a mix 1:1 with chitosan), 1 mcg Synacthen, Nasal spray, solution, Suspension for injection, Synacthen | Sheffield Children's NHS Foundation Trust | In stages 1+2 of the study healthy volunteers will be used to determine the bioequivalence of nasal Synacthen with 1 microgram of intravenous synacthen. Stage 3 will use healthy children to establish normal ranges for the adrenal response to a low-dose synacthen test. In stage 4 adrenal function in asthmatic individuals on inhaled corticosteroids will be studied., Inability to produce the stress hormone, cortisol, is known as adrenal insufficiency. It can cause serious illness and even death. Inhaled steroids taken for asthma can cause adrenal insufficiency., Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01] | | | | |
2006-004045-42: Randomized, Open-Label, Active Controlled, Two-Period Crossover Study To Evaluate Relative Efficacy And Safety of Investigational Captisol-Enabled Budesonide Inhalation Solution (CBIS) Delivered via eFlow Nebuliser and Conventional Budesonide Inhalation Suspension (Pulmicort Respules) Delivered via LC Plus Jet Nebuliser in Adult Patients with Mild To Moderate Persistent Asthma |
|
|
| Ongoing | 1 | 20 | Europe | Captisol-Enabled Budesonide, Pulmicort Respules, CBIS, Pulmicort Respules, Pulmicort Respules | Verus Pharmaceuticals Inc | Asthma | | | | |
2006-003801-21: A Randomised, Open-Label, Active-Controlled, Two-Period Crossover Study to Evaluate Relative Efficacy and Safety of Investigational Captisol-Enabled® Budesonide Inhalation Solution (CBIS) Delivered via eFlow® Nebuliser and Conventional Budesonide Inhalation Suspension (Pulmicort Respules®) Delivered via LC Plus® Jet Nebuliser in Children with Mild-to-Moderate Persistent Asthma |
|
|
| Ongoing | 1 | 20 | Europe | Captisol-Enabled Budesonide, Pulmicort 250 Repsules, CBIS, Pulmicort 250 Repsules, Pulmicort 250 Repsules | Verus Pharmaceuticals Inc | Asthma | | | | |
2006-006736-22: An early diagnosis of asthma in young children by using non-invasive biomarkers of oxidative stress/airway inflammation, and early lung function measurements |
|
|
| | 1 | 200 | Europe | Qvar Extrafijne Aerosol 100 inhalator, Qvar Extrafijne Aerosol 100 inhalator | Netherlands Asthma Foundation (NAF), Stichting astma bestrijding | children with recurrent respiratory symptoms) | | | | |
2009-013355-29: A multi-stage clinical study to develop a non-invasive Short Synacthen Test (SST) with nasally administered synacthen and salivary cortisol. The validated non-invasive SST will be used to establish normative data in children and to detect adrenal suppression in asthmatic children. |
|
|
| Ongoing | 1 | 258 | Europe | Synacthen, Synacthen, Synacthen | Sheffield Children\'s NHS Foundation Hospital | In stages 1+2 of the study healthy volunteers will be used to determine the bioequivalence of nasal synacthen with 1 microgram of intravenous synacthen. Stage 3 will use healthy children to establish normal ranges for the adrenal response to a low-dose synacthen test. In stage 4 adrenal function in asthmatic individuals on inhaled corticosteroids will be studied. | | | | |
2014-001946-10: A research study to find out whether a product to be tested (salmeterol xinafoate HFA pMDI 25 μg per actuation, manufactured by Cipla Ltd, India) is equivalent to the already existing formulation (salmeterol xinafoate HFA pMDI 25 μg per actuation (Serevent Evohaler™), supplied by Allen and Hanburys, UK) when administered by a volumatic spacer device to children with asthma |
|
|
| Ongoing | 1 | 12 | Europe | Salmeterol xinafoate HFA pMDI 25 μg per actuation manufactured by CIPLA, Sereflo™ CFC-free Inhaler™ 25 micrograms per actuation, Serevent™ 25 micrograms Evohaler™, Sereflo™ CFC-free Inhaler™ 25 micrograms per actuation, Serevent™ 25 micrograms Evohaler™ | Cipla Ltd., Cipla Ltd. | Asthma | | | | |
ChiCTR-IPR-14005381: Treating bronchial asthma with crude herb moxibustion: the randomized controlled clinical trials of optimizing drug prescriptions and acupoints combinations |
|
|
| Not yet recruiting | 1 | 80 | | Raw white mustard ointment, Fei shu, Feng men, Ding chuan ;Raw white mustard ointment, Tian tu, Da zhui, Gao huang, Shen shu ;Cooked white mustard ointment, Fei shu, Feng men, Ding chuan ;Cooked white mustard ointment, Fei shu, Feng men, Ding chuan | Xinjiang Autonomous Region Traditional Chinese Medicine Hospital; Level of the institution：, Science and Technology Agency of Xinjiang Autonomous Region | bronchial asthma | | | | |
ChiCTR-OPC-15006416: The effect of prolonged duration of clinic visits on asthma control and patient-doctor relationships |
|
|
| Not yet recruiting | 1 | 200 | | increasing the duration of new clinic visits with an assistant for 20 minutes after the physicians' visit | The Second Xiangya Hospital of Central South University; The Second Xiangya Hospital of Central South University, The ATS MECOR Program | asthma | | | | |
NCT01970085: Asthma Express: Bridging the Emergency to Primary Care in Underserved |
|
|
| Recruiting | 1 | 264 | US | Asthma Express | Arlene M. Butz, National Institute of Nursing Research (NINR) | Asthma in Children | 08/17 | 02/18 | | |
ChiCTR1800014567: Bioequivalence study of salbutamol inhalation aerosol in healthy volunteers |
|
|
| Recruiting | 1 | 42 | | Albuterol aerosol inhaler, 100ug/puff under fasting, T2 puffs ;Albuterol aerosol inhaler,100ug/puff under fasting R 2 puffs | Peking University First Hospital; Sichuan Purity Pharmaceutical technology Co., LTD, Sponsors | Bronchial Asthma | | | | |
ChiCTR1800019111: An open-label, single-dose and single- plus multiple-dose study to assess the pharmacokinetic profile of FLUTIFORM pMDI 50/5 μg (100/10 μg total dose), 125/5 μg (250/10 μg total dose), and 250/10 μg (500/20 μg total dose) in healthy Chinese subjects |
|
|
| Recruiting | 1 | 36 | | FLUTIFORM pMDI single-dose administration (50/5 μg, 125/5 μg, and 250/10 μg) and multiple-dose administration (250/10 μg) | West China Hospital, Sichuan University; Mundipharma (China) Pharmaceutical Co. Ltd, Mundipharma (China) Pharmaceutical Co. Ltd | Asthma | | | | |
ChiCTR1900020710: Preliminary study for bioequivalence of beclomethasone propionate inhaled aerosol at single dose, single center, random, open, four cycles, two sequences and cross human body under carbon and non-carbon conditions |
|
|
| Recruiting | 1 | 18 | | TRTR ; RTRT | Beijing Shijitan Hospital Capital Medical University; BEIJING SL PHARM, BEIJING SL PHARM | asthma | | | | |
FOSTER PK study, ChiCTR1900021899: A randomized, open label, parallel controlled trial for evaluating the pharmacokinetics of different dosage of Foster NEXThaler (beclomethasone dipropionate and formoterol inhalation powder [100/6 μg]) in healthy Chinese subjects |
|
|
| Not yet recruiting | 1 | 36 | | beclomethasone dipropionate and formoterol inhalation powder | West China Hospital, Sichuan University; Mundipharma (China) Pharmaceutical Co. Ltd, Mundipharma (China) Pharmaceutical Co. Ltd | Asthma | | | | |
ChiCTR1800018994: A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose, Single-center Study for Assessment of the Safety, Tolerability and Pharmacokinetic of Litapiprant Tablets in Healthy Subjects --APhase I single dose escalation clinical trial |
|
|
| Recruiting | 1 | 60 | | 25 mg ;50mg ;100mg ;200mg ;400mg ;600mg ;800mg | Beijing Shijitan Hospital Capital Medical University; Sunshine Lake Pharma Co., Ltd., Sunshine Lake Pharma Co., Ltd. | bronchial asthma | | | | |
NCT04746040: A Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers |
|
|
| Active, not recruiting | 1 | 50 | Europe | Test, Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals, Reference, ADVAIR DISKUS 250/50 | Respirent Pharmaceuticals Co Ltd., Becro Ltd. | Bioequivalence, Asthma | 02/21 | 05/21 | | |
| Not yet recruiting | 1 | 12 | | Multiple administration | Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine; TASLY PHARMACEUTICAL GROUP CO., LTD., enterprise | Long-term congestive heart failure caused by chest tightness, asthma, cough, edema, limbs, cold, fatigue | | | | |
| Not yet recruiting | 1 | 38 | | Jiashen tablets ;placebo | The second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine; Tasly pharmaceutical group co., LTD, enterprise | chest tightness, asthma, cough, edema, limbs, cold, fatigue caused by Long-term congestive heart failure | | | | |
NCT05021887: A Bioequivalence Study Between Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 100 mcg/Blister Oral Inhalation Powder /GSK in Healthy Volunteers Under Fasting Conditions |
|
|
| Recruiting | 1 | 50 | Europe | Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals, Test, FLOVENT DISKUS, Reference | Respirent Pharmaceuticals Co Ltd., Becro Ltd. | Asthma, Bioequivalence | 09/21 | 11/21 | | |
NCT05085587: Bioequivalence Study of Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers |
|
|
| Active, not recruiting | 1 | 18 | Europe | Test, Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals, Reference, ADVAIR DISKUS 250/50 | Respirent Pharmaceuticals Co Ltd., Becro Ltd. | Bioequivalence, Asthma | 10/21 | 12/21 | | |
ChiCTR2100046371: A single-dose,dose-escalation, randomized, double-blind, placebo-controlled clinical trial on the tolerability, safety, pharmacokinetics of GR1802 injection in healthy subjects |
|
|
| Recruiting | 1 | 36 | | GR1802 injection/placebo 75mg ;GR1802 injection/placebo 150mg ;GR1802 injection/placebo 300mg ;GR1802 injection/placebo 600mg ;GR1802 injection/placebo 900mg | Phase I Clinical Research Center, Huashan Hospital Affiliated to Fudan University; Genrix (Shanghai) Biopharmaceutical Co., Ltd, self-funded | Atopic Dermatitis;Asthma;Chronic rhinosinusitis with nasal polyps | | | | |
ChiCTR2100043100: Pharmacokinetic study of multiple oral administration of R-Bambuterol hydrochloride tablets in a population with higher plasma butylcholinesterase activity |
|
|
| Recruiting | 1 | 50 | | R-BMB 5mg Q24 for 21 days ;R-BMB 5mg QN for 28 days ;R-BMB 10mg QN for 28 days | Dongguan People's Hospital; Key-Pharma Biomedical Inc., Self-finance | Asthma, COPD | | | | |
ChiCTR2000031925: A multicenter, randomized, double-blind, parallel controlled phase I clinical trial comparing the pharmacokinetic and safety similarities of recombinant anti IgE humanized monoclonal antibody for injection(HS632) with Omalizumab (Xolair?)after a single dose administration in Chinese healthy subjects |
|
|
| Not yet recruiting | 1 | 252 | | Subcutaneous injection of HS632 ;Subcutaneous injection of Omazumab | Huashan Hospital Affiliated to Fudan University; Shanghai Shuguang Hospital, Zhejiang Hisunbioray biopharmaceutical Co., Ltd. | Asthma | | | | |
ChiCTR2100047512: A Randomised, Double Blind Study to Investigate Safety, Tolerability, Pharmacokinetics of Single Dose in Healthy Volunteers of Kudinchocide A Inhalation Solution |
|
|
| Not yet recruiting | 1 | 56 | | Kudinchoside A Inhalation Solution | The Third Hospital of Changsha; Shanghai KE Pharmaceutical Technology Co., Ltd, Sponsor | Bronchial Asthma, Chronic obstructive pulmonary disease | | | | |
NCT04905602: A Trial of SHR-1905 in Healthy Subjects and Subjects With Mild Asthma |
|
|
| Recruiting | 1 | 62 | RoW | SHR-1905/placebo | Shanghai Hengrui Pharmaceutical Co., Ltd. | Asthma | 01/22 | 01/22 | | |
NCT05397834: A Bioequivalence Study Between Fluticasone Propionate 250 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 250 mcg/Blister Oral Inhalation Powder /GSK in Healthy Volunteers Under Fasting Conditions |
|
|
| Active, not recruiting | 1 | 36 | Europe | Fluticasone Propionate 250 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals, Test, FLOVENT DISKUS, Reference | Respirent Pharmaceuticals Co Ltd., Becro Ltd. | Asthma, Bioequivalence | 06/22 | 09/22 | | |
NCT05170243: A Clinical Study in Healthy Subjects to Evaluate 9MW1911 Injection |
|
|
| Completed | 1 | 28 | RoW | 9MW1911 Injection, 9MW1911 Injection Placebo | Mabwell (Shanghai) Bioscience Co., Ltd. | Asthma, COPD, Atopic Dermatitis | 07/22 | 10/22 | | |
NCT05171348: A Multiple Ascending Doses Study of CM326 Injection in Healthy Subjects |
|
|
| Completed | 1 | 40 | RoW | CM326, Placebo | Keymed Biosciences Co.Ltd | Asthma | 10/22 | 10/22 | | |
| Completed | 1 | 50 | RoW | SHR-1905, Placebo | Atridia Pty Ltd. | Asthma | 11/22 | 11/22 | | |
NCT04929626: Different Doses of Nebulized Magnesium Sulphate in Status Asthmaticus |
|
|
| Completed | 1 | 126 | RoW | Magnesium Sulfate 500 mg/ml+ ventolin, MgSO4, Ventolin, Salbutamol | Ziauddin University | Status Asthmaticus | 11/22 | 11/22 | | |
NCT04108377: Phosphodiesterase 4 Inhibitor, Roflumilast, and the Effects of Inhibition in Severe Asthma |
|
|
| Terminated | 1 | 5 | US | Roflumilast, Daliresp, Placebo, Placebo for Roflumilast | University of California, Davis | Asthma | 12/22 | 08/23 | | |
NCT05140200: Study of GSK3511294 in Healthy Chinese Participants |
|
|
| Completed | 1 | 20 | RoW | GSK3511294 | GlaxoSmithKline | Asthma | 12/22 | 12/22 | | |
ChiCTR2000038734: Transcription factor BHLHE40 plays a role in the regulation of cellular inflammation and pyroptosis in asthma. |
|
|
| Not yet recruiting | 1 | 90 | | no ;no ;no | Affiliated Nanhai Hospital, Southern Medical University (People's Hospital of Nanhai District); Affiliated Nanhai Hospital, Southern Medical University, Guangdong Basic and Applied Basic Research Fund Project (Regional Joint Fund-Youth Fund Project), 2019A1515110563 | asthma | | | | |
ChiCTR2100047781: Phase i, single-center, randomized, double-blind, parallelity-controlled clinical trial comparing pharmacokinetic and safety comparability of recombinant anti-IgE humanized monoclonal antibody for injection (HS632) with omalizumab( Xolair) after single dose administration in healthy Chinese subjects |
|
|
| Not yet recruiting | 1 | 62 | | Subcutaneous injection of HS632 ;Subcutaneous injection of Omazumab | The First Affiliated Hospital of Guangzhou University of Chinese Medicine; Zhejiang haizheng pharmaceutical co. LTD, self-raised | Asthma | | | | |
NCT05449535: Study of JYB1904 (an Anti-immunoglobulin E Antibody) in Healthy Chinese Subjects |
|
|
| Completed | 1 | 56 | RoW | JYB1904, Omalizumab, Xolair, JYB1904 Placebo | Jemincare | Healthy | 01/23 | 01/23 | | |
NCT04769869: A Clinical Trial in Healthy Volunteers and Patients With Mild Asthma to Investigate a New Medicine (AZD4604) for the Treatment of Asthma |
|
|
| Completed | 1 | 110 | Europe | AZD4604 for inhalation via DPI, Placebo for AZD4604 for inhalation via DPI, AZD4604 for IV administration, AZD4604 for oral administration | AstraZeneca | Asthma | 01/23 | 01/23 | | |
NCT05366764: First-in-human Study of SAR443765 in Healthy Participants and in Asthmatic Participants |
|
|
| Completed | 1 | 36 | Europe | SAR443765, Placebo, Salbutamol or levosalbutamol | Sanofi | Asthma | 02/23 | 02/23 | | |
NCT04993443: First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036 |
|
|
| Terminated | 1 | 40 | RoW | LQ036, Matching Placebo, Matching Placebo for LQ036 | Syneos Health, Shanghai Novamab Biopharmaceuticals Co. Ltd. | Asthma | 03/23 | 03/23 | | |
NCT04619017: Airway Immune Response to Allergens (Use Lay Language Here) |
|
|
| Active, not recruiting | 1 | 12 | US | Segmental allergen challenge | JOSALYN CHO, Massachusetts General Hospital | Allergic Asthma, Allergy to Cats, Allergy to Dust Mites, Allergic Rhinitis, Allergic Conjunctivitis | 04/23 | 03/24 | | |
| Terminated | 1 | 34 | Europe, US | MRx-4DP0004, Placebo | 4D pharma plc | Asthma | 04/23 | 04/23 | | |
| Active, not recruiting | 1 | 117 | Europe | KN-002 | Kinaset Therapeutics Inc | Asthma COPD | 12/23 | 04/24 | | |
NCT05791565: Green (Sustainable) VENTOLIN - Pharmacokinetics (PK) Study in Healthy Participants |
|
|
| Completed | 1 | 28 | Europe | Salbutamol HFA-152a, Salbutamol HFA-134a | GlaxoSmithKline | Asthma | 05/23 | 05/23 | | |
NCT05576454: Evaluate the Pharmacokinetics of BAT2606 Injection in Healthy Chinese Male Subjects |
|
|
| Completed | 1 | 207 | RoW | Mepolizumab Injection (BAT2606 Injection), BAT2606 Injection, Mepolizumab Injection (EU-licensed Nucala), EU-licensed Nucala, Mepolizumab Injection (US-licensed Nucala), US-licensed Nucala | Bio-Thera Solutions | Severe Asthma | 05/23 | 06/23 | | |
NCT05803902: An Evaluation of 9MW1911 Injection in Healthy Subjects |
|
|
| Active, not recruiting | 1 | 48 | RoW | Experimental drug 9MW1911, Placebo | Mabwell (Shanghai) Bioscience Co., Ltd. | Asthma, COPD, Atopic Dermatitis | 06/23 | 06/23 | | |
NCT06449859: A Clinical Trial of TQC2938 Injection in Healthy Adult Subjects |
|
|
| Active, not recruiting | 1 | 84 | RoW | TQC2938 Injection, TQC2938 Placebo | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Asthma | 11/24 | 11/24 | | |
| Active, not recruiting | 1 | 23 | RoW | SHR-1703, placebo | Jiangsu HengRui Medicine Co., Ltd. | Asthma | 06/23 | 06/23 | | |
ChiCTR2200063120: A single-center, randomized, double-blind, placebo-controlled phase Ia clinical trial to evaluate the tolerability, safety, immunogenicity and pharmacokinetics of transoral inhalation of nebulized LQ036 in healthy Chinese subjects |
|
|
| Not yet recruiting | 1 | 64 | | Single oral inhalation of LQ036 (dose 1) or placebo ;Single-dose transoral inhalation of LQ036 (dose level 2) or placebo ;Single-dose transoral inhalation of LQ036 (dose level 3) or placebo ;Single-dose transoral inhalation of LQ036 (dose level 4) or placebo ;Single-dose transoral inhalation of LQ036 (dose level 5) or placebo ;Transoral inhalation of LQ036 (dose level a) or placebo, QD. ;Transoral inhalation of LQ036 (dose level b) or placebo, QD. ;Transoral inhalation of LQ036 (dose level c) or placebo, QD. | The Second Hospital of Anhui Medical University; The Second Hospital of Anhui Medical University, Shanghai Novamab Biopharmaceuticals Co., Ltd. | bronchial asthma | | | | |
NCT05794672: A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Elarekibep in Healthy Japanese Subjects |
|
|
| Terminated | 1 | 30 | Europe | Elarekibep, AZD1402, Placebo | AstraZeneca, Parexel | Healthy Subjects (Indication: Asthma) | 07/23 | 07/23 | | |
NCT05110976: A Study to Investigate the Safety, Tolerability and Effects of AZD8630 in Healthy Subjects and Subjects With Asthma on Inhaled Corticosteroids and Long-acting Beta-agonists |
|
|
| Completed | 1 | 170 | Europe, US | AZD8630, Placebo | AstraZeneca | Asthma | 08/23 | 08/23 | | |
NCT05898984: Clinical Study to Evaluate the Safety, Tolerability and the Concentration of the BDP (Beclomethasone Dipropionate), Active Metabolite of BDP, FF( Formoterol Fumarate) and GB (Glycopyrronium Bromide), After Inhalation of CHF 5993 at Two Different Doses and QVAR® |
|
|
| Recruiting | 1 | 69 | Europe | Test product (T):CHF 5993 BDP/FF/GB 200/6/12.5 µg pMDI, Reference product 1 (R1): CHF 5993 BDP/FF/GB 100/6/12.5 µg pMDI, Trimbow Medium Strenght (MS)®, Reference product 2 (R2): BDP HFA (QVAR REDIHALER®, BDP 80 μg), QVAR REDIHALER® | Chiesi Farmaceutici S.p.A., SGS S.A. | Asthma | 08/23 | 08/23 | | |
NCT05448651: Safety and Biologic Impact (Pharmacodynamics) of Repeated Injections and Increasing Amounts of UPB-101 in Asthmatics |
|
|
| Completed | 1 | 32 | Europe | UPB-101, Formerly ASP7266, Placebo, 0.9% saline solution | Upstream Bio Inc. | Asthma | 08/23 | 10/23 | | |
NCT05659927: Single Dose Clinical Trial of MG-ZG122 in Chinese Healthy Adult Subjects |
|
|
| Active, not recruiting | 1 | 34 | RoW | MG-ZG122 Humanized Monoclonal Antibody Injection, MG-ZG122, Placebo | Shanghai Mabgeek Biotech.Co.Ltd | Asthma | 01/24 | 03/24 | | |
| Not yet recruiting | 1 | 96 | RoW | TQC2731, Placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Asthma Severe Persistent Controlled | 08/23 | 08/23 | | |
NCT05584306: A Dose Ranging Placebo-controlled Double-blind Study to Evaluate the Safety, Pharmacokinetics and Efficacy of 610 in Participants With Severe Eosinophilic Asthma |
|
|
| Active, not recruiting | 1 | 24 | RoW | 610 30mg group, 610 100mg group, 610 300mg group, Placebo 30mg group, Placebo 100mg group, Placebo 300mg group | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Asthma | 09/23 | 09/23 | | |
NCT05332834: A Phase 1 Study of Single and Multiple Intravenous Doses of SM17 in Healthy Subjects |
|
|
| Recruiting | 1 | 78 | US | SM17, Placebo | SinoMab BioScience Ltd | 1. Asthma | 09/23 | 10/23 | | |
| Recruiting | 1 | 50 | RoW | HBM9378 (SKB378) Injection, Placebo | Harbour BioMed (Guangzhou) Co. Ltd. | Asthma | 09/23 | 09/23 | | |
NCT05830071: A Thorough QT (TQT) Study of CHF5993 pMDI in Healthy Volunteers (HV) |
|
|
| Completed | 1 | 95 | US | CHF5993, beclometasone dipropionate /formoterol fumarate/glycopyrronium bromide, BDP/FF/GB, CHF5259, glycopyrronium bromide, GB, Moxifloxacin 400mg, Moxifloxacin hydrochloride, CHF5993 Placebo, BDP/FF/GB Placebo | Chiesi Farmaceutici S.p.A. | Asthma, Chronic Obstructive Pulmonary Disease (COPD) | 10/23 | 10/23 | | |
NCT04082754: A Clinical Study to Test the Safety, Exposure, and Pharmacodynamic Markers of CSL311 in Patients With Mild-to-moderate Asthma and in Healthy Volunteers |
|
|
| Completed | 1 | 78 | Europe | Human beta common receptor antagonist monoclonal antibody, CSL311, Placebo | CSL Behring | Asthma | 11/23 | 11/23 | | |
ChiCTR2200062411: A Phase I, Single-Center, Randomized, Double-Blind, Single-Dose Incremental, Placebo-Controlled Study of QX008N for the Safety, Tolerability, Pharmacokinetics and Immunogenicity in Healthy Volunteers. |
|
|
| Not yet recruiting | 1 | 44 | | QX008N injection ;Placebo | Zhongshan Hospital of Fudan University; Jiangsu Qyuns Therapeutics Co., Ltd., Qyuns therapeutics CO.,LTD. | Adults with Severe, poorly controlled asthma | | | | |
NCT05954611: The Study of Single Dose Administration of GR2002 Injection in Chinese Health Volunteers |
|
|
| Recruiting | 1 | 50 | RoW | GR2002 injection, Placebo | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Asthma | 11/23 | 11/23 | | |
NCT06137040: Timely Administration of IV Magnesium Sulfate in Patients With a Moderate Asthma Exacerbation |
|
|
| Recruiting | 1 | 100 | US | Magnesium Sulfate within the first hour, Magnesium within the first hour, No Magnesium sulfate within the first hour, No magnesium within the first hour | University of Oklahoma | Asthma in Children, Asthma Attack | 08/24 | 08/24 | | |
| Recruiting | 1 | 104 | Europe, RoW | ARO-MUC5AC, Placebo | Arrowhead Pharmaceuticals, Arrowhead Pharmaceuticals, Inc. | Asthma, Chronic Obstructive Pulmonary Disease | 11/24 | 11/24 | | |
| Recruiting | 1 | 149 | Europe, RoW | ARO-RAGE, Placebo | Arrowhead Pharmaceuticals, Arrowhead Pharmaceuticals, Inc. | Asthma | 12/24 | 02/25 | | |
| Completed | 1 | 43 | RoW | ARO-RAGE Injection, Placebo | Arrowhead Pharmaceuticals | Asthma | 02/24 | 02/24 | | |
NCT02748798: Developing Optimal Parameters for Hyperpolarized Noble Gas and Inert Fluorinated Gas MRI of Lung Disorders |
|
|
| Recruiting | 1 | 160 | Canada | HP 3He, Hyperpolarized helium 3, HP 129Xe, Hyperpolarized xenon 129, PFP, Perfluoropropane, SF6, Sulfur hexafluoride, 129Xe Small and Large Human Lung Coil, 3He Human Lung Coil, PFP and SF6 Human Lung Coil | Thunder Bay Regional Health Research Institute, Thunder Bay Regional Health Sciences Centre, St. Joseph's Care Group, Lakehead University | Lung Transplant, Lung Resection, Lung Cancer, Asthma, Cystic Fibrosis, Chronic Obstructive Pulmonary Disease, Emphysema, Mesothelioma, Asbestosis, Pulmonary Embolism, Interstitial Lung Disease, Pulmonary Fibrosis, Bronchiectasis, Seasonal Allergies, Cold Virus, Lung Infection, Pulmonary Hypertension, Pulmonary Dysplasia, Obstructive Sleep Apnea | 12/23 | 12/23 | | |
| Completed | 1 | 47 | US | Mitoquinol, MitoQ, Placebo oral tablet | University of Vermont, Duke University | Asthma, Obesity | 03/24 | 03/24 | | |
NCT05564221: A Multiple Ascending Dose, Phase 1b Study of YH35324 in Atopic Healthy Subjects or Subjects With Allergic Diseases |
|
|
| Recruiting | 1 | 43 | RoW | YH35324, Placebo, Omalizumab, Xolair® prefilled syringe 150 for injection | Yuhan Corporation | Atopic Healthy Subjects, Adult Subjects With Allergic Diseases | 12/24 | 12/24 | | |
NCT05602025: A Study to Compare the Pharmacokinetics (PK) of Depemokimab When Delivered With a Safety Syringe Device (SSD) or an Autoinjector in Healthy Adult Participants |
|
|
| Completed | 1 | 140 | US | Depemokimab | GlaxoSmithKline, PPD | Asthma | 10/23 | 10/23 | | |
ChiCTR2300067857: Safety, tolerability, and pharmacokinetic profiles of MG-ZG122 humanized monoclonal antibody injection administered as a single subcutaneous injection in healthy Chinese adult volunteers: a single-center, randomized, double-blind, placebo-controlled, dose-escalating phase I clinical study |
|
|
| Not yet recruiting | 1 | 34 | | MG-ZG122 (dosage 1) vs placebo ;MG-ZG122 (dosage 2) vs placebo ;MG-ZG122 (dosage 3) vs placebo ;MG-ZG122 (dosage 4) vs placebo | The Second Hospital of Anhui Medical University; Shanghai Mabgeek Biotechnology Co., LTD., Shanghai Mabgeek Biotechnology Co., LTD. | asthma, chronic obstructive pulmonary disease | | | | |
NCT06157255: An ADME Study of [14C]AZD4604 and the Absolute Bioavailability of AZD4604 |
|
|
| Completed | 1 | 8 | Europe | AZD4604 Inhalation Powder, 1 mg, AZD4604, [14C]AZD4604 Solution for Infusion 6 μg/mL (NMT 37.0 kBq/5 mL), [14C]AZD4604 Oral Solution, 4 mg (NMT 37.0 kBq) | AstraZeneca, Quotient Sciences | Asthma | 05/24 | 05/24 | | |
NCT06213844: A First-in-human, Single-ascending-dose Study of IBI3002 in Healthy Participants and Mild to Moderate Asthmatics |
|
|
| Recruiting | 1 | 52 | RoW | IBI3002, ICS, alone or in combination with LABA, Placebo | Innovent Biologics (Suzhou) Co. Ltd. | Healthy Participants, Asthma | 02/25 | 02/25 | | |
NCT06319183: The Regulatory Function of Inhaled Asthma Medication Salbutamol on Thermogenesis |
|
|
| Not yet recruiting | 1 | 30 | NA | Salbutamol | Tongji University | Effect of Asthma Medication Salbutamol on Obesity | 06/24 | 03/25 | | |
| Recruiting | 1 | 70 | RoW | Halotherapy (Salt Therapy) | Igdir University | Therapy, Oxygen Inhalation | 05/24 | 06/24 | | |
ChiCTR2300069500: Phase Ia clinical study to evaluate the tolerability, safety, pharmacokinetic profiles and immunogenicity of LQ043H single-domain antibody nebulizer after a single dose in healthy Chinese subjects |
|
|
| Not yet recruiting | 1 | 40 | | Single nebulised inhalation test drug dose 1 (vs placebo) ;placebo (Single nebulised inhalation test drug dose 1) ;Single nebulised inhalation test drug dose 2 (vs placebo) ;placebo (Single nebulised inhalation test drug dose 2) ;Single nebulised inhalation test drug dose 3 (vs placebo) ;placebo (Single nebulised inhalation test drug dose 3) ;Single nebulised inhalation test drug dose 4 (vs placebo) ;placebo (Single nebulised inhalation test drug dose 4) ;Single nebulised inhalation test drug dose 5 (vs placebo) ;placebo (Single nebulised inhalation test drug dose 5) | The Second Hospital of Anhui Medical University; Shanghai Novamab Biopharmaceuticals Co., Ltd., Shanghai Novamab Biopharmaceuticals Co., Ltd. | Bronchial Asthma | | | | |
| Not yet recruiting | 1 | 60 | US | Lipopolysaccharides, Endotoxin, LPS, Clinical reference center lipopolysaccharide, LPS E. Coli O:113 | National Jewish Health | Asthma; Eosinophilic, Asthma | 04/28 | 06/28 | | |
NCT06385964: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SHR-4597 Inhalation in Healthy Subjects and Asthmatic Patients |
|
|
| Not yet recruiting | 1 | 80 | NA | SHR-4597, Placebo | Guangdong Hengrui Pharmaceutical Co., Ltd | Healthy Subjects, Asthmatic Patients | 12/24 | 01/25 | | |
NCT05398198: Efficacy and Safety of GSK3923868 Inhalation Powder, During Experimental Human Rhinovirus Infection in Participants With Mild Asthma |
|
|
| Completed | 1 | 48 | Europe | GSK3923868, Placebo | GlaxoSmithKline | Pulmonary Disease, Chronic Obstructive | 04/24 | 04/24 | | |
NCT00595491: Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation |
|
|
| Recruiting | 1 | 313 | US | Bronchoscopy, Segmental Allergen Challenge, and Broncheoalveolar Lavage, One of 3 Standardized allergen extracts will be used:, Standardized Cat Hair Extract, Standardized mite extract-Dermatophagoides farinae, Standardized mite extract-Dermatophagoides pteronyssinus, Phenolized saline diluent will also be used in this study., All will be purchased from Greer Laboratories Lenoir,NC. | Benjamin Medoff, National Institutes of Health (NIH), U.S. Army Medical Research and Development Command | Asthma | 04/24 | 07/24 | | |
NCT06290102: Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulfate in Combination When Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Children Aged 4 to 11 Years Old |
|
|
| Recruiting | 1 | 22 | US | TEV-56248, - fluticasone propionate/albuterol sulfate multidose dry powder inhaler with e-module (Fp/ABS eMDPI), Fp MDPI, - fluticasone propionate multidose dry powder inhaler | Teva Branded Pharmaceutical Products R&D, Inc. | Asthma | 10/24 | 11/24 | | |
NCT06433908: A Study to Compare the Pharmacokinetics (PK) of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152A (Test) or HFA-134A (Reference) in Healthy Participants Aged 18 to 55 Inclusive |
|
|
| Not yet recruiting | 1 | 60 | Europe | Salbutamol HFA-152a, Salbutamol HFA-134a | GlaxoSmithKline | Asthma, Healthy Participants | 09/24 | 09/24 | | |
| Enrolling by invitation | 1 | 60 | US | Nutritional approach for asthma, MCT supplement, Low Caloric Shake, whole lung allergen challenge | The Cleveland Clinic | Asthma, Allergic Asthma, Non-allergic Asthma | 06/25 | 06/25 | | |
NCT06433921: A Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152a to HFA-134a in Mild Asthmatics Aged 18 to 65 Inclusive |
|
|
| Not yet recruiting | 1 | 91 | NA | Salbutamol HFA-152a, Salbutamol HFA-134a, Placebo | GlaxoSmithKline | Asthma, Mild Asthma | 10/24 | 10/24 | | |
ChiCTR2300070472: A Phase Ib, Multicenter, Randomized, Double-Blind, Multi-Dose Escalation, Placebo-Controlled Study Investigating the Efficacy, Safety, Tolerability, Pharmacokinetics and Immunogenicity of QX008N in the Adults with Moderate to Severe Asthma |
|
|
| Not yet recruiting | 1 | 30 | | QX008N injection ;Placebo | Zhongshan Hospital of Fudan University; Jiangsu Qyuns Therapeutics Co., Ltd., Self-funded | Adults with severe, poorly controlled asthma | | | | |
NCT03567707: Vaginal Microbiome Exposure and Immune Responses in C-section Infants |
|
|
| Recruiting | 1 | 120 | US | C-section -Vaginal seeding, vaginal microbiota, maternal vaginal microbiota, C-section - Placebo Seeding, placebo vaginal microbiota, standard care, standard of care | National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN), PPD, Rho Federal Systems Division, Inc. | Allergic Diseases, Asthma | 01/25 | 01/27 | | |
| Withdrawn | 1 | 30 | US | Dexamethasone Oral | IDeA States Pediatric Clinical Trials Network, National Institutes of Health (NIH), University of Nebraska | Bronchiolitis | 03/25 | 04/25 | | |
ChiCTR2300070586: A randomized, open-label, parallel, single-dose, single-center, phase I clinical study evaluating the pharmacokinetic characteristics, safety and immunogenicity of subcutaneous injection and intravenous infusion of QX008N injection in healthy subjects |
|
|
| Not yet recruiting | 1 | 36 | | Subcutaneous injection QX008N 280 mg ;Subcutaneous injection QX008N 560 mg ;Intravenous injection QX008N 560 mg | Shulan (Hangzhou) Hospital; Jiangsu Qyuns Therapeutics Co., Ltd., Self-funded | Adults with Severe, poorly controlled asthma | | | | |
ChiCTR2300072816: A randomized, double-blind, placebo-controlled, dose-exploration, multicenter phase II clinical trial of Jiuwei Shufeng Pingchuan Granules in the treatment of chronic persistent bronchial asthma (wind asthma syndrome) |
|
|
| Not yet recruiting | 1 | 240 | | Jiuwei Shufeng Pingchuan Granules ;Jiuwei Shufeng Pingchuan Granule + Simulator ;Jiuwei Shufeng Pingchuan Granule + Simulator | The First Affiliated Hospital of He'nan University of Traditional Chinese Medicine; The First Affiliated Hospital of He'nan University of Traditional Chinese Medicine, Enterprise | Chronic Duration of Bronchial Asthma (Wind Asthma Syndrome) | | | | |
NCT05035862: Mechanisms of Interferon Gamma-primed Mesenchymal Stromal Cells (MSCs) for Moderate-to-severe Persistent Asthma |
|
|
| Recruiting | 1 | 12 | US | Albuterol Sulfate, Interferon gamma-primed mesenchymal stromal cells (MSCs), Interferon gamma (IFNγ)-primed human bone marrow-derived mesenchymal stromal cells, Prednisone | Emory University, The Marcus Foundation, Ossium Health, Inc. | Asthma | 07/25 | 12/25 | | |
NCT04624490: Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease |
|
|
| Recruiting | 1 | 260 | US | Hyperpolarized Xe129, HP Xenon | Mario Castro, MD, MPH | Asthma, COPD, Interstitial Lung Disease, Cystic Fibrosis, Pulmonary Hypertension, Pulmonary Infection, Other Lung Disease | 10/25 | 10/26 | | |
NCT05147688: Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Pulmonary Diseases |
|
|
| Recruiting | 1 | 20 | RoW | AlloRx | The Foundation for Orthopaedics and Regenerative Medicine | Pulmonary Disease, Asthma, Chronic Obstructive Pulmonary Disease | 12/25 | 12/25 | | |
ChiCTR2300074829: Randomized, double-blind, parallel controlled, multicenter clinical trial on the efficacy and safety of Qingjin Pingchuan Tang in the treatment of children with bronchial asthma during the onset stage (heat induced asthma syndrome) in combination with Maxing Shigan Tang and Suting Wan group |
|
|
| Not yet recruiting | 1 | 300 | | to "qingjinpingchuan"soup ;to "maxingganshi and suting"soup | Children's Hospital, Zhejiang University School of Medicine; Children's Hospital, Zhejiang University School of Medicine, Funded by Provincial Science and Technology Department | childhood bronchial asthma | | | | |
NCT03926741: GSNOR Phenotyping/GSNO Challenge in Severe Asthma |
|
|
| Completed | 1 | 49 | US | GSNO | James Reynolds, University Hospitals Cleveland Medical Center, Case Western Reserve University, National Heart, Lung, and Blood Institute (NHLBI) | Asthma, Healthy Volunteers | 02/24 | 02/24 | | |
